logo-loader

Kazia Therapeutics shares boom in New York after orphan drug status news

Last updated: 09:26 23 Feb 2018 EST, First published: 04:26 23 Feb 2018 EST

1519396147_neuroscience-2
Glioblastoma multiforme is the most aggressive form of brain cancer

Shares in Kazia Therapeutics Ltd (NASDAQ:KZIA, ASX:KZA), an oncology-focused biotech firm, saw shares add 10% in New York after the all powerful US FDA gave it key orphan drug status.

It was for its new investigational drug GDC-0084 for the treatment of glioblastoma multiforme - the most aggressive form of brain cancer.

Imminent start of Phase II clinical study

Glioblastoma multiforme (GBM) is an area of significant unmet medical need. More than 130,000 patients are diagnosed worldwide each year, and the prognosis remains poor.

Orphan drug designation (ODD) is a special status accorded to candidates, which are considered promising potential treatments for rare, or orphan diseases, generally defined as those which affect less than 200,000 cases per year in the United States.

It also provides potential for grant funding and financial benefits, such as a waiver of new drug application fees, and tax credits.

"We are very pleased to have successfully completed this important regulatory step in the development of GDC-0084," said Kazia chief executive Dr James Garner.

"We share FDA's recognition of the need for new treatments in this very challenging disease, and we believe that GDC-0084 has great promise as a potential new therapy.

"We anticipate an imminent start of the phase II clinical study, and look forward to working closely with the participating clinicians."

Ramp Metals Launches Drilling Program in Pursuit of High-Grade Nickel in...

Ramp Metals CEO Jordan Black joined Steve Darling from Proactive to introduce the company to the public domain and share exciting developments in the mining industry. With a background as a geotechnical engineer and experience in venture capital, including a notable role in taking GoldSpot...

1 hour, 27 minutes ago